P093 Infliximab Reintroduction in Patients With Inflammatory Bowel Disease Previously Treated With a 3-Infusion Induction Regimen Is Not Associated to a Higher Rate of Immune-Mediated Adverse Effects

Zabana, Yamile; Domènech, Eugeni; Cabré, E.; Mañosa, Míriam; García‐Castellanos, Raquel; Carriün, S.; Ortiz, T.; Gassull, M. A.

doi:10.1016/s1873-9954(08)70104-6

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intermittent therapy may predispose to formation of anti-drug antibodies and increased loss of response (Baert 2003). On the other hand, Zabana et al found no difference in LOR between patients receiving scheduled IFX maintenance therapy to those reintroduced to IFX after a period of 4 months of no therapy in patients who received the original 3 infusion induction regimen (15% versus 10% respectively), suggesting this issue needs further evaluation (Zabana 2008).…”

Section: Prevention Of Anti-tnf Therapy Failurementioning

confidence: 99%

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Allez

Karmiris

Louis

et al. 2010

Journal of Crohn's and Colitis

289

197

View full text Add to dashboard Cite

The first ECCO pathogenesis workshop focused on anti-TNF therapy failures in inflammatory bowel diseases (IBDs). The overall objective was to better understand and explore primary non response and loss of response to anti-TNF agents in IBD. The outcome of this workshop is presented into two parts. This first section addresses definitions, frequency and pharmacological aspects of anti-TNF therapy failure, including pharmacokinetics of anti-TNF monoclonal antibodies and immune and non-immune mediated clearance of anti-TNF mAbs. The second section concerns the biological roles of TNF and TNF antagonists, including mechanisms of action of anti-TNF agents, and discuss hypothesis regarding their failures and phenomenon of paradoxical inflammation, including the potential role of TNF independent inflammatory pathways.

show abstract

Section: Prevention Of Anti-tnf Therapy Failurementioning

confidence: 99%

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Allez

Karmiris

Louis

et al. 2010

Journal of Crohn's and Colitis

289

197

View full text Add to dashboard Cite

show abstract

“…123 Infliximab reintroduction after a period of drug discontinuation (more than 4 months) in patients previously treated with a three infliximab induction regimen (at weeks 0, 2, and 6) was not associated with a higher incidence of secondary loss of response, compared to those receiving infliximab maintenance treatment. 124 In this study, infliximab was restarted after a median of 13 months. Loss of response occurred in 15% of the maintenance group and 10% in the ''reintroduction'' group.…”

Section: Dosing Intervalsmentioning

confidence: 99%

Practical application of anti-TNF therapy for luminal Crohnʼs disease

Kamm

Cruz

et al. 2011

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Anti-tumor necrosis factor (TNF) therapy to treat inflammatory bowel disease has been available for more than a decade. Although extensive data on the outcome of anti-TNF therapy from individual clinical trials and patient cohorts are available, integrated guidance on the best use of such therapy to achieve optimal clinical outcomes when managing patients with luminal Crohn's disease is lacking. This review combines published data to establish practical strategies for anti-TNF therapy with respect to effective and safe timing of introduction, use of concurrent immunosuppressive therapy, dose escalation, managing relapse, changing drugs, pregnancy and breast feeding, and stopping drug treatment.

show abstract

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

2009

View full text Add to dashboard Cite

A variable but relevant proportion of Crohn's disease patients on long-term infliximab treatment lose response. This may be interpreted in two different but compatible ways: a positive view, highlighting that infliximab therapy is relatively durable, with the majority of patients predicted to continue infliximab treatment at least during the first year; or a negative view, interpreting that a significant proportion of Crohn's disease patients-more than 10% per patient-year of infliximab treatment-on long term will lose response and will require an increase in dose and/or decrease in infusion interval.

show abstract

P093 Infliximab Reintroduction in Patients With Inflammatory Bowel Disease Previously Treated With a 3-Infusion Induction Regimen Is Not Associated to a Higher Rate of Immune-Mediated Adverse Effects

Cited by 4 publications

References 0 publications

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Practical application of anti-TNF therapy for luminal Crohnʼs disease

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

Contact Info

Product

Resources

About